English articles
Treatment
PEA influences PPAR
| PEA influences PPAR |
|
One of the explanations regarding the workingmechanism of PEA (palmitoylethanolamide) is that this drug influences PPAR-alpha. PPAR-apha is a receptor located in the nucleus of the cel with a long name: peroxisome proliferator-activatedreceptor alpha.
In the beginning of the nineties the nucleic receptors, like PPAR-alpha, have been descoverd.[1][2] The search of this receptor started, because scientists wanted to know the mechanism of action of the molecules on which they did research. These molecules could lower the lipids in blood serum, influence the fat burning, and stimulate the production ofperoxisomes.[3][4][5] The name of the PPAR receptor originates of one of its actions: Proliferation of the Peroxisome Activated Receptor, PPAR. Peroxisomes are vesicles in the cell, especially liver cells, containing hydrogenperoxide. The hydrogenperoxide in the vesicles breaks down toxic substances, like alcohol. PPAR's have many functions and have a nickname: sensors for stress situations.[6] Thus molecules that influence PPAR are very interesting. PEA influences PPAR-alphaOne of the actions of PPAR-alfa is this receptor regulates inflammation.[7] Because clinical and laboratory studies have shown that PEA has an anit-inflammatory action, Italian researchers conducted a laboratory experiment on rats to find out whether PEA influences PPAR-alfa. In This experiment showed indeed that PEA affects PPAR-alfa.[8] Rats without the PPAR-alfa, did not show any reduction on the evoked inflamation, after receiving PEA. This might suggest that the anti-inflamatory action of PEA is mediated through the PPAR-alfa. An other experiment with an allergic skin inflammation rat model showed that PEA is a natural substance with anti-inflammatory effects.[9] PPAR stimulation supresses the production of INF-gamma and IL-17 through CD4+ Thelper-cells (immune cells), and the inhibition of migration of lymphocytes (white blood cells) to the place of inflammation, through inhibition of the production of chemokines(attraction molecules).[10] Not only does supresses PEA the inflammation mediated by PPAR-alfa, PEA also has a clear pain reducing effect in several pain models. [11] Influencing the genes by PPAR-alpha and supressing inflammaton takes houres, compared to the pain reduction which takes place immediately. Experiments in pain models show that the combination PEA and PPAR-alpha has a direct effect on the potasium channels of nerve cells. PEA has a neuroprotective effect through PPAR-alphaThe neuroprotective effect of PEA has already been shown. That this mechanism is mediated by PPAR-alfa has been shown in a German laboratory study. Researchers used brain tissue to examine the effect of PEA.[12] Blocking the PPAR-alpha receptor with a drug. blocking the receptor, eliminated the protective effect of PEA. Also memory enhancement of PEA has been monitored in a rat model.[13] David J. Kopsky, MD, October 2010 Referenties[1]: Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. | Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. | Cell. | 1992 Mar 6;68(5):879-87. [2]: Issemann I, Green S. | Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. | Nature. | 1990 Oct 18;347(6294):645-50. [3]: Reddy JK, Krishnakantha TP. | Hepatic peroxisome proliferation: induction by two novel compounds structurally unrelated to clofibrate. | Science. | 1975 Nov 21;190(4216):787-9. [4]: Lalwani ND, Alvares K, Reddy MK, Reddy MN, Parikh I, Reddy JK. | Peroxisome proliferator-binding protein: identification and partial characterization of nafenopin-, clofibric acid-, and ciprofibrate-binding proteins from rat liver. | Proc Natl Acad Sci U S A. | 1987 Aug;84(15):5242-6. [5]: Lalwani ND, Fahl WE, Reddy JK. | Detection of a nafenopin-binding protein in rat liver cytosol associated with the induction of peroxisome proliferation by hypolipidemic compounds. | Biochem Biophys Res Commun. | 1983 Oct 31;116(2):388-93. [6]: Yessoufou A, Wahli W. | Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. | Swiss Med Wkly. | 2010 Sep 15;140:w13071. doi: 10.4414/smw.2010.13071. [7]: Kostadinova R, Wahli W, Michalik L. | PPARs in diseases: control mechanisms of inflammation. | Curr Med Chem. | 2005;12(25):2995-3009. [8]: Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D. | The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. | Mol Pharmacol. | 2005 Jan;67(1):15-9. Epub 2004 Oct 1. [9]: Petrosino S, Cristino L, Karsak M, Gaffal E, Ueda N, Tüting T, Bisogno T, De Filippis D, D'Amico A, Saturnino C, Orlando P, Zimmer A, Iuvone T, Di Marzo V. | Protective role of palmitoylethanolamide in contact allergic dermatitis. | Allergy. | 2010 Jun 1;65(6):698-711. Epub 2009 Nov 11. [10]: Straus DS, Glass CK. | Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. | Trends Immunol. | 2007 Dec;28(12):551-8. Epub 2007 Nov 5. [11]: LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G, Meli R, Hohmann A, Calignano A, Piomelli D. | Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. | J Pharmacol Exp Ther. | 2006 Dec;319(3):1051-61. Epub 2006 Sep 22. [12]: Koch M, Kreutz S, Böttger C, Benz A, Maronde E, Ghadban C, Korf HW, Dehghani F. | Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferator-activated receptor-alpha. | Neurotox Res. | 2011 Feb;19(2):330-40. Epub 2010 Mar 11. [13]: Mazzola C, Medalie J, Scherma M, Panlilio LV, Solinas M, Tanda G, Drago F, Cadet JL, Goldberg SR, Yasar S. | Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors. | Learn Mem. | 2009 Apr 29;16(5):332-7. Print 2009 May. |